NZ784224A - Parp1 inhibitors - Google Patents

Parp1 inhibitors

Info

Publication number
NZ784224A
NZ784224A NZ784224A NZ78422420A NZ784224A NZ 784224 A NZ784224 A NZ 784224A NZ 784224 A NZ784224 A NZ 784224A NZ 78422420 A NZ78422420 A NZ 78422420A NZ 784224 A NZ784224 A NZ 784224A
Authority
NZ
New Zealand
Prior art keywords
methyl
compound
ethyloxo
naphthyridinyl
piperazinyl
Prior art date
Application number
NZ784224A
Other versions
NZ784224B2 (en
Inventor
Martin Packer
Jeffrey Johannes
Sudhir Hande
Sebastien Degorce
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NZ784224A publication Critical patent/NZ784224A/en
Publication of NZ784224B2 publication Critical patent/NZ784224B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine. The compounds of Formula (I) are selective inhibitors of PARP1 and are useful in the treatment of cancer

Claims (17)

Claims:
1) A compound of formula (Ia) wherein 10 R1 is C1-4 alkyl, R2 is ed from H, halo, C1-4 alkyl, and C1-4 fluoroalkyl, R3 is H or C1-4 alkyl, and R4 is H; or a pharmaceutically acceptable salt thereof. 15
2) The compound or a pharmaceutically able salt thereof according to claim 1 wherein R2 is selected from difluoromethyl, trifluoromethyl, or methyl.
3) The compound or a pharmaceutically able salt thereof according to claim 1 wherein R2 is H or halo.
4) The compound or a pharmaceutically acceptable salt thereof according to claim 1 wherein R1 20 is ethyl, R2 is selected from H, chloro and fluoro, and R3 is methyl.
5) The compound or a pharmaceutically acceptable salt thereof according to claim 1 selected from: 5-[4-[(7-ethyloxo-5H-1,5-naphthyridinyl)methyl]piperazinyl]-N-methyl-pyridinecarboxamide, 5-[4-[(7-ethyloxo-5H-1,5-naphthyridinyl)methyl]piperazinyl]fluoro-N-methyl-pyridine 25 carboxamide, 6-chloro[4-[(7-ethyloxo-5H-1,5-naphthyridinyl)methyl]piperazinyl]-N-methyl-pyridine carboxamide, and 5-[4-[(7-ethyloxo-5H-1,5-naphthyridinyl)methyl]piperazinyl]pyridinecarboxamide.
6) The compound or a pharmaceutically acceptable salt f according to claim 1, n the 30 compound is 5-[4-[(7-ethyloxo-5H-1,5-naphthyridinyl)methyl]piperazinyl]-N-methyl-pyridine carboxamide having the structure: 5 , or a pharmaceutically acceptable salt f.
7) The compound according to claim 1, wherein the compound is 5-[4-[(7-ethyloxo-5H-1,5- naphthyridinyl)methyl]piperazinyl]-N-methyl-pyridinecarboxamide having the structure: 10 8) The compound or a pharmaceutically acceptable salt thereof according to claim 1 which is selected from: 6-(difluoromethyl)[4-[(7-ethyloxo-5H-1,5-naphthyridinyl)methyl]piperazinyl]-N-methylpyridinecarboxamide 5-[4-[(7-ethyloxo-5H-1,5-naphthyridinyl)methyl]piperazinyl]-N-methyl-6 15 (trifluoromethyl)pyridinecarboxamide, 5-[4-[(7-ethyloxo-5H-1,5-naphthyridinyl)methyl]piperazinyl]-N,6-dimethyl-pyridine carboxamide, and
N-ethyl[4-[(7-ethyloxo-5H-1,5-naphthyridinyl)methyl]piperazinyl]pyridinecarboxamide.
9) A pharmaceutical ition comprising a compound or a pharmaceutically acceptable salt 20 thereof according to any of claims 1 to 8, and at least one pharmaceutically able diluent, excipient or inert carrier.
10) Use of the compound or a pharmaceutically acceptable salt thereof according to any of claims 1 to 8, in the manufacture of a ment for the treatment of cancer in a cancer patient.
11) The use according to claim 10, wherein said cancer is deficient in homologous recombination 25 dependent DNA dual strand break repair pathway.
12) The use according to claim 10, wherein said cancer comprises one or more cancer cells having a reduced or abrogated ability to repair DNA dual strand break by gous recombination relative to normal cells.
13) The use ing to claim 12, wherein said cancer cells have a BRCA1 or BRCA2 deficient 30 phenotype. 5
14) The use according to claim 13, wherein said cancer cells are deficient in BRCA1 or BRCA2.
15) The use according to claim 14, wherein said patient is zygous for a mutation in a gene encoding a component of the HR dependent DNA DSB repair pathway.
16) The use according to claim 15, n said patient is heterozygous for a mutation in BRCA1 and/or BRCA2. 10
17) The use according to any one of claims 10 to 16 wherein the cancer is selected from any one of breast, ovary, pancreas, prostate, hematological, gastrointestinal, and lung cancer. XRPD ctogram for Examgle 4 — Form A 30000 20000 (Counts) 1 0000 5 10 20 30 2-Theta - Scale DSC trace for Example 4 — Form A (\Mg) o 50 100 150 200 250 300 EXO UP Temperature (°C)
NZ784224A 2020-07-17 Parp1 inhibitors NZ784224B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962876065P 2019-07-19 2019-07-19
PCT/EP2020/070306 WO2021013735A1 (en) 2019-07-19 2020-07-17 Parp1 inhibitors

Publications (2)

Publication Number Publication Date
NZ784224A true NZ784224A (en) 2025-12-19
NZ784224B2 NZ784224B2 (en) 2026-03-20

Family

ID=

Also Published As

Publication number Publication date
CL2022000110A1 (en) 2022-09-20
MY208549A (en) 2025-05-14
EP3999506B1 (en) 2025-01-15
JP2022541483A (en) 2022-09-26
RS66682B1 (en) 2025-05-30
US20220227768A1 (en) 2022-07-21
UY38793A (en) 2021-02-26
CO2022001590A2 (en) 2022-03-18
ES3021859T3 (en) 2025-05-27
AU2020318599A1 (en) 2022-03-10
BR112022000534A2 (en) 2022-05-10
MA57972B1 (en) 2025-05-30
HRP20250373T1 (en) 2025-05-23
IL289534A (en) 2022-03-01
JOP20220008A1 (en) 2023-01-30
IL289534B2 (en) 2025-03-01
PL3999506T3 (en) 2025-05-26
PE20221339A1 (en) 2022-09-13
EP3999506A1 (en) 2022-05-25
CR20220070A (en) 2022-03-21
HUE071067T2 (en) 2025-07-28
CA3145644A1 (en) 2021-01-28
US12606555B2 (en) 2026-04-21
KR102929356B1 (en) 2026-02-23
LT3999506T (en) 2025-04-10
CN114144413A (en) 2022-03-04
IL289534B1 (en) 2024-11-01
FI3999506T3 (en) 2025-04-08
TW202116750A (en) 2021-05-01
TWI837403B (en) 2024-04-01
MX2022000711A (en) 2022-02-23
SMT202500146T1 (en) 2025-05-12
DOP2022000006A (en) 2022-03-15
US11325906B2 (en) 2022-05-10
SI3999506T1 (en) 2025-06-30
AU2020318599B2 (en) 2023-09-07
CN114144413B (en) 2024-08-16
PH12022550098A1 (en) 2022-11-21
US20210040084A1 (en) 2021-02-11
PT3999506T (en) 2025-04-09
DK3999506T3 (en) 2025-04-14
AR119424A1 (en) 2021-12-15
EP4529952A3 (en) 2025-06-25
UA129093C2 (en) 2025-01-08
EP4529952A2 (en) 2025-04-02
KR20220035941A (en) 2022-03-22
ECSP22012826A (en) 2022-03-31
JP7641944B2 (en) 2025-03-07
WO2021013735A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
MY208549A (en) Parp1 inhibitors
ZA202405294B (en) Heterocyclic compounds as immunomodulators
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
JOP20180039A1 (en) Pd?1/pd?l1 inhibitors
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2021001186A (en) Purinones as ubiquitin-specific protease 1 inhibitors.
ZA201603342B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX387885B (en) Ezh2 inhibitors for treating lymphoma
NZ733174A (en) Quinazoline derivatives used to treat hiv
MY199705A (en) Heterocyclic compounds as immunomodulators
MX2017009571A (en) Heterocyclic itk inhibitors for treating inflammation and cancer.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX379621B (en) Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer
SG10201902664RA (en) Combination therapy for treating cancer
EA201892075A1 (en) COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
PH12022550130A1 (en) Enzyme inhibitors
MY202884A (en) Compounds useful in hiv therapy
MX2021001612A (en) Compounds useful in hiv therapy.
PH12022550118A1 (en) Enzyme inhibitors
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
MX2020005344A (en) Pyrazolopyridinone compounds.
MX2020005342A (en) Pyrazolopyridinone compounds.
MX2020000135A (en) New quinolinone compounds.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
PH12021552389A1 (en) Quinoline derivatives and their use for the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed